Publication

5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

Robert, C
; 
Schachter, J
; 
Long, GV
; 
Arance, A
; 
Grob, JJ
; 
Mortier, L
; 
Daud, A
; 
Carlino, MS
; 
McNeil, C
; 
Lotem, M
... show 10 more
Citations
Altmetric:
Abstract
Authors
Robert, C
Schachter, J
Long, GV
Arance, A
Grob, JJ
Mortier, L
Daud, A
Carlino, MS
McNeil, C
Lotem, M
Larkin, J
Lorigan, Paul C
Neyns, B
Blank, CU
Hamid, O
Petrella, TM
Anderson, J
Krepler, C
Diede, SJ
Ribas, A
Affiliation
Gustave Roussy and Paris-Sud University, Villejuif,
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Robert C, Schachter J, Long G, Arance A, Grob J, Mortier L, et al. 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Cancer Res. 2019;79(13).
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622425
Embedded videos